Wilson Sonsini Goodrich & Rosati advised Excision BioTherapeutics on the deal.Excision BioTherapeutics, a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, announced…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
